2-(Morpholin-4-yl)isonicotinic acid → 5-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-[1-(2-morpholin-4-ylisonicotinoyl)piperidin-4-yl]-2,4-dihydro-3H-pyrazol-3-one

Beteiligte Stoffe

Rolle	Name	HCID	Einwaage
Edukt	2-(Morpholin-4-yl)isonicotinic acid	HCID 2762479	—
Edukt	5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-piperidin-4-yl-2,4-dihydro-3H-pyrazol-3-one hydrochloride	HCID 66616406	—
Produkt	5-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-[1-(2-morpholin-4-ylisonicotinoyl)piperidin-4-yl]-2,4-dihydro-3H-pyrazol-3-one	HCID 46204966	—

Reaktionsschritte

The title compound is prepared analogously as described for GP2-WU2 using 5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-(piperidin-4-yl)-2,4-dihydro-3H-pyrazol-3-one (compound B1) and 2-morpholin-4-ylisonicotinic acid as starting compounds. The crude product is purified by chromatography (silica gel and DCM/methanol=95:5) to yield the title compound.

Herkunft & Nachweise

DOI	10.6084/m9.figshare.5104873.v1
Patentnummer	US09340522B2
Quelldatensatz	uspto-grants-2016_05
ORD ID	ord-43a54989f460473a95f74f66986c3310
Quellennotiz	uspto-grants-2016_05